Recent Events & Catalysts
Ultragenyx Pharmaceutical Inc. (RARE) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Ultragenyx Pharmaceutical And Baylor Research Institute Reach Settlement Agreement With Esjay Pharma To Resolve Patent Litigation Related To The Company’s DOJOLVI Oral Liquid; Esjay Granted Non-Exclus
Benzinga · today
HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $50 Price Target
Benzinga · 1d ago
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
Yahoo · 6d ago
Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $45
Benzinga · 6d ago
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript
SeekingAlpha · 6d ago
Ultragenyx Pharmaceutical Inc (RARE) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Yahoo · 6d ago
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Yahoo · 6d ago
Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise
ChartMill · 6d ago
SEC Filings (90 days)
Other events
Filed 2026-08-11 · 0d ago
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-04 · 7d ago · Material
Departure/appointment of directors or officers, Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-05-18 · 85d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.